As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
22 Analysts have issued a United Therapeutics Corporation forecast:
22 Analysts have issued a United Therapeutics Corporation forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 3,128 3,128 |
14%
14%
|
|
| Gross Profit | 2,772 2,772 |
13%
13%
|
|
| EBITDA | 1,605 1,605 |
13%
13%
|
|
| EBIT (Operating Income) EBIT | 1,522 1,522 |
13%
13%
|
|
| Net Profit | 1,272 1,272 |
14%
14%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
| Head office | United States |
| CEO | Martine Rothblatt |
| Employees | 1,305 |
| Founded | 1996 |
| Website | www.unither.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


